A Mathematical Model Describes the Malignant Transformation of Low Grade Gliomas: Prognostic Implications

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Aug 2

PMID 28763450

Citations 21

Authors

Magdalena U Bogdanska

Marek Bodnar

Monika J Piotrowska

Michael Murek

Philippe Schucht

Jurgen Beck

Alicia Martinez-Gonzalez

Victor M Perez-Garcia

Affiliations

Soon will be listed here.

Abstract

Gliomas are the most frequent type of primary brain tumours. Low grade gliomas (LGGs, WHO grade II gliomas) may grow very slowly for the long periods of time, however they inevitably cause death due to the phenomenon known as the malignant transformation. This refers to the transition of LGGs to more aggressive forms of high grade gliomas (HGGs, WHO grade III and IV gliomas). In this paper we propose a mathematical model describing the spatio-temporal transition of LGGs into HGGs. Our modelling approach is based on two cellular populations with transitions between them being driven by the tumour microenvironment transformation occurring when the tumour cell density grows beyond a critical level. We show that the proposed model describes real patient data well. We discuss the relationship between patient prognosis and model parameters. We approximate tumour radius and velocity before malignant transformation as well as estimate the onset of this process.

Citing Articles

XAI-MRI: an ensemble dual-modality approach for 3D brain tumor segmentation using magnetic resonance imaging.

Farhan A, Khalid M, Manzoor U Front Artif Intell. 2025; 8:1525240.

PMID: 40046502 PMC: 11880613. DOI: 10.3389/frai.2025.1525240.

Exploring adult glioma through MRI: A review of publicly available datasets to guide efficient image analysis.

Abbad Andaloussi M, Maser R, Hertel F, Lamoline F, Husch A Neurooncol Adv. 2025; 7(1):vdae197.

PMID: 39877749 PMC: 11773385. DOI: 10.1093/noajnl/vdae197.

Expressions of the satellite repeat HSAT5 and transposable elements are implicated in disease progression and survival in glioma.

Kose S, Yaras T, Bursali A, Oktay Y, Yandim C, Karakulah G Turk J Biol. 2024; 48(4):242-256.

PMID: 39296333 PMC: 11407350. DOI: 10.55730/1300-0152.2700.

DataXflow: Synergizing data-driven modeling with best parameter fit and optimal control - An efficient data analysis for cancer research.

Crouch S, Krause J, Dandekar T, Breitenbach T Comput Struct Biotechnol J. 2024; 23:1755-1772.

PMID: 38707537 PMC: 11068525. DOI: 10.1016/j.csbj.2024.04.010.

Focus on current and emerging treatment options for glioma: A comprehensive review.

Lucke-Wold B, Rangwala B, Shafique M, Siddiq M, Mustafa M, Danish F World J Clin Oncol. 2024; 15(4):482-495.

PMID: 38689623 PMC: 11056857. DOI: 10.5306/wjco.v15.i4.482.

References

Mazzocco P, Barthelemy C, Kaloshi G, Lavielle M, Ricard D, Idbaih A . Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics. CPT Pharmacometrics Syst Pharmacol. 2016; 4(12):728-37. PMC: 4759703. DOI: 10.1002/psp4.54. View

Pouratian N, Schiff D . Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010; 10(3):224-31. PMC: 2857752. DOI: 10.1007/s11910-010-0105-7. View

Bondiau P, Clatz O, Sermesant M, Marcy P, Delingette H, Frenay M . Biocomputing: numerical simulation of glioblastoma growth using diffusion tensor imaging. Phys Med Biol. 2008; 53(4):879-93. DOI: 10.1088/0031-9155/53/4/004. View

SKELLAM J . Random dispersal in theoretical populations. Biometrika. 1951; 38(1-2):196-218. View

Pouratian N, Gasco J, Sherman J, Shaffrey M, Schiff D . Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol. 2006; 82(3):281-8. DOI: 10.1007/s11060-006-9280-4. View

Chaichana K, McGirt M, Laterra J, Olivi A, Quinones-Hinojosa A . Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg. 2009; 112(1):10-7. DOI: 10.3171/2008.10.JNS08608. View

Swanson K, Rockne R, Claridge J, Chaplain M, Alvord Jr E, Anderson A . Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology. Cancer Res. 2011; 71(24):7366-75. PMC: 3398690. DOI: 10.1158/0008-5472.CAN-11-1399. View

Wang C, Rockhill J, Mrugala M, Peacock D, Lai A, Jusenius K . Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Res. 2009; 69(23):9133-40. PMC: 3467150. DOI: 10.1158/0008-5472.CAN-08-3863. View

Bobek-Billewicz B, Stasik-Pres G, Hebda A, Majchrzak K, Kaspera W, Jurkowski M . Anaplastic transformation of low-grade gliomas (WHO II) on magnetic resonance imaging. Folia Neuropathol. 2014; 52(2):128-40. DOI: 10.5114/fn.2014.43784. View

10.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

11.

Jalbert L, Neill E, Phillips J, Lupo J, Olson M, Molinaro A . Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro Oncol. 2016; 18(8):1169-79. PMC: 4933480. DOI: 10.1093/neuonc/now008. View

12.

Gannett D, Wisbeck W, Silbergeld D, Berger M . The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys. 1994; 30(3):567-73. DOI: 10.1016/0360-3016(92)90942-b. View

13.

Swanson K, Harpold H, Peacock D, Rockne R, Pennington C, Kilbride L . Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle. Clin Oncol (R Coll Radiol). 2008; 20(4):301-8. DOI: 10.1016/j.clon.2008.01.006. View

14.

Gerin C, Pallud J, Deroulers C, Varlet P, Oppenheim C, Roux F . Quantitative characterization of the imaging limits of diffuse low-grade oligodendrogliomas. Neuro Oncol. 2013; 15(10):1379-88. PMC: 3779035. DOI: 10.1093/neuonc/not072. View

15.

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

16.

Barazzuol L, Burnet N, Jena R, Jones B, Jefferies S, Kirkby N . A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. J Theor Biol. 2009; 262(3):553-65. DOI: 10.1016/j.jtbi.2009.10.021. View

17.

Galochkina T, Bratus A, Perez-Garcia V . Optimal radiation fractionation for low-grade gliomas: Insights from a mathematical model. Math Biosci. 2015; 267:1-9. DOI: 10.1016/j.mbs.2015.05.006. View

18.

Perez-Garcia V, Perez-Romasanta L . Extreme protraction for low-grade gliomas: theoretical proof of concept of a novel therapeutical strategy. Math Med Biol. 2015; 33(3):253-71. DOI: 10.1093/imammb/dqv017. View

19.

Frazier J, Johnson M, Burger P, Weingart J, Quinones-Hinojosa A . Rapid malignant transformation of low-grade astrocytomas: report of 2 cases and review of the literature. World Neurosurg. 2010; 73(1):53-62. DOI: 10.1016/j.surneu.2009.05.010. View

20.

Sakarunchai I, Sangthong R, Phuenpathom N, Phukaoloun M . Free survival time of recurrence and malignant transformation and associated factors in patients with supratentorial low-grade gliomas. J Med Assoc Thai. 2014; 96(12):1542-9. View